MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CAIN, B. F.
Right arrow Articles by BAGULEY, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CAIN, B. F.
Right arrow Articles by BAGULEY, B. C.

Molecular Pharmacology, Vol 12, 1027-1035, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Structure-Activity Relationships for Thiolytic Cleavage Rates of Antitumor Drugs in the 4'-(9-Acridinylamino) methanesulfonanilide Series

BRUCE F. CAIN 1, WILLIAM ROBERT WILSON 1, and BRUCE C. BAGULEY 1

1 Cancer Chemotherapy Laboratory, P. O. Box 1724, Auckland, New Zealand, and Department of Cell Biology, University of Auckland, Auckland, New Zealand

4'-(9-Acridinylamino)methanesulfon-m-anisidide (NSC 156303; m-AMSA) is an experimental broad-spectrum antitumor agent also displaying immunosuppressive and antiviral activity. In pharmacological studies this compound had a short half-life in vivo as a result of rapid chemical reaction with proteins. Interaction of m-AMSA with thiols and other nucleophiles has been studied and the reaction products characterized. The reaction of greatest biological relevance is nucleophilic attack at the acridine C-9 position by thiols. The relationships among structure, thiolysis rates, and antileukemic activity of over 50 substituted acridines have been investigated. Rapid reaction with thiols is not a prerequisite for antileukemic (L1210) activity with these agents.

Submitted on March 2, 1976
Accepted on July 6, 1976






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics